Immunis, Inc.
Wednesday, June 05, 2024
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 1
Immunis is a private biotechnology company researching and developing secretome products to address age-driven immune dysfunction. Our investigational secretome product, IMMUNA, leverages our leading-edge capabilities in cell culture to deliver a product of all natural, all human immune modulators in their natural relative concentrations. Immunis is currently testing the effects of IMMUNA in a Phase 1/2a clinical trial for muscle atrophy.
Company Website:
http://www.immunisbiomedical.com
Lead Product in Development:
IMMUNA (formerly known as IMM01-STEM)
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Company HQ City
Irvine
Company HQ State
CA
Company HQ Country
United States
CEO/Top Company Official
Hans Keirstead, PhD
Development Phase of Primary Product
Phase I
Primary Speaker
.png)
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())